Stocktoria
Mirum Pharmaceuticals, Inc. MIRM
Mirum Pharmaceuticals, Inc. financials (annual)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $521.3M | $336.9M | $186.4M | $77.1M | $19.1M | $0 | — |
| SG&A expense | $257.0M | $202.2M | $145.9M | $89.1M | $59.2M | — | — |
| Operating income | -$22.1M | -$87.6M | -$109.2M | -$131.2M | -$173.4M | -$104.3M | -$54.7M |
| Income tax | $1.9M | $1.0M | $991,000 | -$6.4M | $37,000 | $6,000 | $21,000 |
| Net income | -$23.4M | -$87.9M | -$163.4M | -$135.7M | -$84.0M | -$103.3M | -$52.6M |
| EPS (diluted) | $-0.47 | $-1.85 | $-4.00 | $-4.02 | $-2.77 | — | — |
| Operating cash flow | $55.8M | $10.3M | -$70.9M | -$120.1M | -$132.8M | -$89.1M | -$39.4M |
| Free cash flow | $54.9M | $9.3M | -$71.1M | -$120.4M | -$132.8M | -$89.3M | -$39.6M |
| Cash & equivalents | $296.7M | $222.5M | $286.3M | $28.0M | $31.3M | $142.1M | $12.0M |
| Inventory | $24.9M | $22.4M | $22.3M | $5.6M | $1.5M | $0 | — |
| Total assets | $842.8M | $670.8M | $646.6M | $352.9M | $294.7M | $240.9M | $146.7M |
| Total liabilities | $528.1M | $445.1M | $398.0M | $210.9M | $174.4M | $68.8M | $16.4M |
| Shareholders' equity | $314.7M | $225.6M | $248.7M | $142.0M | $120.2M | $172.1M | $130.3M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth | +54.7% | +80.8% | +141.8% | +302.7% | — | — | — |
| Free cash flow growth | +488.0% | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.